BRPI0406985A - Terapia de combinação de hcv - Google Patents

Terapia de combinação de hcv

Info

Publication number
BRPI0406985A
BRPI0406985A BR0406985-4A BRPI0406985A BRPI0406985A BR PI0406985 A BRPI0406985 A BR PI0406985A BR PI0406985 A BRPI0406985 A BR PI0406985A BR PI0406985 A BRPI0406985 A BR PI0406985A
Authority
BR
Brazil
Prior art keywords
combination therapy
hcv combination
hcv
hepreceptor
ezrine
Prior art date
Application number
BR0406985-4A
Other languages
English (en)
Inventor
Rupert Donald Holms
Ravshan Inoyatov Ataullakhanov
Original Assignee
Regent Res L L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regent Res L L P filed Critical Regent Res L L P
Publication of BRPI0406985A publication Critical patent/BRPI0406985A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TERAPIA DE COMBINAçãO DE HCV". Um peptídeo, que possui pelo menos 80% de identidade com um fragmento de Domínio A ou B do Hepreceptor de ezrina, é utilizado com um interferon, como uma preparação combinada para o uso simultâneo, separado ou seq³encial no tratamento de hepatite antiviral.
BR0406985-4A 2003-01-27 2004-01-27 Terapia de combinação de hcv BRPI0406985A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0301879.3A GB0301879D0 (en) 2003-01-27 2003-01-27 HCV combination therapy
PCT/GB2004/000330 WO2004067024A2 (en) 2003-01-27 2004-01-27 Hcv combination therapy

Publications (1)

Publication Number Publication Date
BRPI0406985A true BRPI0406985A (pt) 2006-01-10

Family

ID=9951908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406985-4A BRPI0406985A (pt) 2003-01-27 2004-01-27 Terapia de combinação de hcv

Country Status (13)

Country Link
US (1) US20060067913A1 (pt)
EP (1) EP1587531A2 (pt)
JP (1) JP2006515011A (pt)
KR (1) KR20050101184A (pt)
CN (1) CN1738639A (pt)
AU (1) AU2004208541A1 (pt)
BR (1) BRPI0406985A (pt)
CA (1) CA2511562A1 (pt)
GB (1) GB0301879D0 (pt)
IL (1) IL169322A0 (pt)
MX (1) MXPA05007901A (pt)
NO (1) NO20053189L (pt)
WO (1) WO2004067024A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180560T1 (hr) 2015-06-01 2018-05-04 Nearmedic International Limited Peptidi derivati ezrina i njihove farmaceutske kompozicije
RU2694906C2 (ru) * 2016-06-01 2019-07-18 Ниармедик Интернэшнл Лимитед Пептиды производные эзрина и фармацевтические композиции на их основе
US12629405B2 (en) 2020-04-01 2026-05-19 Pantapharm Ag Ezrin peptide 1 for use in a method of treating COVID-19
AU2022247001A1 (en) 2021-03-31 2023-10-05 Pantapharm Ag Ezrin peptide 1 for use in a method of treating post covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (pt) * 1991-09-13 1994-05-21 Paul B Chretien
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB2354241A (en) * 1999-09-17 2001-03-21 Rupert Donald Holms Regulatory/unfolding peptides of ezrin

Also Published As

Publication number Publication date
JP2006515011A (ja) 2006-05-18
WO2004067024A3 (en) 2004-09-16
AU2004208541A1 (en) 2004-08-12
CA2511562A1 (en) 2004-08-12
NO20053189L (no) 2005-08-24
IL169322A0 (en) 2007-07-04
KR20050101184A (ko) 2005-10-20
NO20053189D0 (no) 2005-06-29
WO2004067024A2 (en) 2004-08-12
US20060067913A1 (en) 2006-03-30
MXPA05007901A (es) 2005-09-21
CN1738639A (zh) 2006-02-22
GB0301879D0 (en) 2003-02-26
EP1587531A2 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
BR0112540A (pt) Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
ES2186660T3 (es) Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
BRPI0410467A (pt) composições e métodos para tratamento de sìndrome respiratória aguda severa (sars)
NO20034878L (no) Antivirale forbindelser
BRPI0409632A (pt) combinações antineoplásticas
BR0306820A (pt) Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus
BR9907882A (pt) Uso de compostos de 1,5-didesóxi-1,5-imino-d-glucitol n-substituìdos para o tratamento de infecções de vìrus de hepatite
PA8587801A1 (es) Isomeros posicionales de interferon alfa 2-a monopegilado
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
AR052056A1 (es) Tratamiento antiangiogenico de enfermedades autoinmunitarias en pacientes que no han respondido a untratamiento previo
MXPA05007901A (es) Terapia de combinacion para hcv.
DE50204475D1 (de) Präparationen von vitamin e in kombination mit afamin
BR0010499A (pt) Agentes endoparasiticidas
BRPI0416105A (pt) uso da bh4 para o tratamento de doença respiratórias
DE60321554D1 (de) Neue analoga von nitrobenzylthioinosin
DE602004009166D1 (de) Neue Analoga von Nitrobenzylthioinosin
DE60033783D1 (de) Regulatorische/entfaltende peptide von ezrin
DE60224280D1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.